Literature DB >> 17116866

Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease.

Vincent Ries1, Claire Henchcliffe, Tatyana Kareva, Margarita Rzhetskaya, Ross Bland, Matthew J During, Nikolai Kholodilov, Robert E Burke.   

Abstract

Despite promising preclinical studies, neurotrophic factors have not yet achieved an established role in the treatment of human neurodegenerative diseases. One impediment has been the difficulty in providing these macromolecules in sufficient quantity and duration at affected sites. An alternative approach is to directly activate, by viral vector transduction, intracellular signaling pathways that mediate neurotrophic effects. We have evaluated this approach in dopamine neurons of the substantia nigra, neurons affected in Parkinson's disease, by adeno-associated virus 1 transduction with a gene encoding a myristoylated, constitutively active form of the oncoprotein Akt/PKB. Adeno-associated virus Myr-Akt has pronounced trophic effects on dopamine neurons of adult and aged mice, including increases in neuron size, phenotypic markers, and sprouting. Transduction confers almost complete protection against apoptotic cell death in a highly destructive neurotoxin model. Activation of intracellular neurotrophic signaling pathways by vector transfer is a feasible approach to neuroprotection and restorative treatment of neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116866      PMCID: PMC1654135          DOI: 10.1073/pnas.0606401103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

Review 1.  Methods for determining numbers of cells and synapses: a case for more uniform standards of review.

Authors:  R E Coggeshall; H A Lekan
Journal:  J Comp Neurol       Date:  1996-01-01       Impact factor: 3.215

2.  Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase.

Authors:  N N Ahmed; H L Grimes; A Bellacosa; T O Chan; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 3.  Pharmacological actions of 6-hydroxydopamine.

Authors:  R M Kostrzewa; D M Jacobowitz
Journal:  Pharmacol Rev       Date:  1974-09       Impact factor: 25.468

Review 4.  Turning behaviour in animals.

Authors:  C J Pycock
Journal:  Neuroscience       Date:  1980       Impact factor: 3.590

5.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.

Authors:  T F Franke; S I Yang; T O Chan; K Datta; A Kazlauskas; D K Morrison; D R Kaplan; P N Tsichlis
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

Review 6.  Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.

Authors:  M J Zigmond; E D Abercrombie; T W Berger; A A Grace; E M Stricker
Journal:  Trends Neurosci       Date:  1990-07       Impact factor: 13.837

7.  Regulation of neuronal survival by the serine-threonine protein kinase Akt.

Authors:  H Dudek; S R Datta; T F Franke; M J Birnbaum; R Yao; G M Cooper; R A Segal; D R Kaplan; M E Greenberg
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

8.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

Authors:  L F Lin; D H Doherty; J D Lile; S Bektesh; F Collins
Journal:  Science       Date:  1993-05-21       Impact factor: 47.728

9.  Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase.

Authors:  S P Soltoff; S L Rabin; L C Cantley; D R Kaplan
Journal:  J Biol Chem       Date:  1992-08-25       Impact factor: 5.157

10.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

Authors:  H Sauer; W H Oertel
Journal:  Neuroscience       Date:  1994-03       Impact factor: 3.590

View more
  69 in total

Review 1.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

2.  AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.

Authors:  Sang Ryong Kim; Tatyana Kareva; Olga Yarygina; Nikolai Kholodilov; Robert E Burke
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.

Authors:  Chee Yeun Chung; James B Koprich; Shogo Endo; Ole Isacson
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

4.  A neuroprotective role for angiogenin in models of Parkinson's disease.

Authors:  Trent U Steidinger; David G Standaert; Talene A Yacoubian
Journal:  J Neurochem       Date:  2010-12-22       Impact factor: 5.372

Review 5.  Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease.

Authors:  Robert E Burke
Journal:  Pharmacol Ther       Date:  2007-02-27       Impact factor: 12.310

6.  Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.

Authors:  Haruhisa Inoue; Ling Lin; Xinhua Lee; Zhaohui Shao; Shannon Mendes; Pamela Snodgrass-Belt; Harry Sweigard; Tom Engber; Blake Pepinsky; Lichuan Yang; M Flint Beal; Sha Mi; Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 7.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

8.  Glutamate controls growth rate and branching of dopaminergic axons.

Authors:  Yvonne Schmitz; James Luccarelli; Minji Kim; Mi Wang; David Sulzer
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

9.  Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo.

Authors:  Tobias Gyárfás; Juha Knuuttila; Päivi Lindholm; Tomi Rantamäki; Eero Castrén
Journal:  Cell Mol Neurobiol       Date:  2009-09-24       Impact factor: 5.046

10.  Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.

Authors:  Cristina Malagelada; Zong Hao Jin; Vernice Jackson-Lewis; Serge Przedborski; Lloyd A Greene
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.